For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback